Home > Journals > Minerva Cardioangiologica > Past Issues > Minerva Cardioangiologica 2020 October;68(5) > Minerva Cardioangiologica 2020 October;68(5):415-35

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe PROMO
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as

 

REVIEW  PCI HOT TOPICS 

Minerva Cardioangiologica 2020 October;68(5):415-35

DOI: 10.23736/S0026-4725.20.05188-9

Copyright © 2020 EDIZIONI MINERVA MEDICA

language: English

Latest generation stents: is it time to revive the bioresorbable scaffold?

Andrea BUONO 1 , Alfonso IELASI 1, Antonio COLOMBO 2

1 Unit of Interventional and Clinical Cardiology, S. Ambrogio Cardio-Thoracic Center, Milan, Italy; 2 GVM Care and Research, Maria Cecilia Hospital, Cotignola, Ravenna, Italy



Bioresorbable scaffolds (BRS) have been introduced in the last decade in percutaneous coronary interventions. Despite several advantages being postulated, the negative results from the mid-term follow-up of the Absorb trials have tempered enthusiasm for these innovative devices. The Absorb scaffold was associated with higher rates of target-lesion failure and scaffold thrombosis when compared to current metallic stents, and for this reason was withdrawn from the market. This failure has to be considered multifactorial, involving technical and technological aspects. Continuous engineering refinements in BRS technology, means newer-generation devices are available in clinical practice, and several more are under preclinical and clinical assessment. Thinner and smaller struts, associated with a faster resorption and reendothelialization process, are at the basis of promising preclinical results for new BRS. In this review we summarize the Absorb scaffold experience and focus on the latest evidence concerning emerging new BRS, to explore if a “BRS revival” is conceivable.


KEY WORDS: Percutaneous coronary intervention; Coronary artery disease; Stents

top of page